Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer

Objective To analyze the short- and long-term effect of chemoradiotherapy combined with rhAd-p53 on locally advanced cervical cancer (LACC). Methods A total of 51 patients with stage ⅡA-ⅣA LACC were divided into experimental group (chemoradiotherapy+rhAd-p53 gene therapy, RCT-p53) and control group...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	DONG Yaqin, XU Xingyu, CHEN Bo, YANG Lin
Formato:	article
Lenguaje:	ZH
Publicado:	Magazine House of Cancer Research on Prevention and Treatment 2021
Materias:	cervical cancer gene therapy radiation therapy chemical treatment rhad-p53 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1a67fba653174b679da54844332a8ff8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a67fba653174b679da54844332a8ff8
record_format	dspace
spelling	oai:doaj.org-article:1a67fba653174b679da54844332a8ff82021-11-05T02:22:52ZEfficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer1000-857810.3971/j.issn.1000-8578.2021.21.0273https://doaj.org/article/1a67fba653174b679da54844332a8ff82021-10-01T00:00:00Zhttp://html.rhhz.net/ZLFZYJ/html/8578.2021.21.0273.htmhttps://doaj.org/toc/1000-8578Objective To analyze the short- and long-term effect of chemoradiotherapy combined with rhAd-p53 on locally advanced cervical cancer (LACC). Methods A total of 51 patients with stage ⅡA-ⅣA LACC were divided into experimental group (chemoradiotherapy+rhAd-p53 gene therapy, RCT-p53) and control group (chemoradiotherapy, RCT). Short-term effect, long-term effect and early side-effect were evaluated. Results ORR of RCT-p53 group and RCT group were 91.7% and 62.9%, respectively (P=0.037); CR rates were 66.7% and 40.7%, respectively. There was no significant difference of early side-effects between two groups, in terms of hematologic toxicity, digestive toxicity, hepatotoxicity or renal toxicity. Five-year PFS of RCT-p53 group and RCT group were 79.8% and 51.3%, respectively (P=0.028); 5-year OS were 81.6% and 60.3%, respectively (P=0.061). Conclusion rhAd-p53 treatment has better short-term effect and long-term effect than concurrent chemoradiotherapy, without increasing early side effects.DONG YaqinXU XingyuCHEN BoYANG LinMagazine House of Cancer Research on Prevention and Treatmentarticlecervical cancergene therapyradiation therapychemical treatmentrhad-p53Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHZhongliu Fangzhi Yanjiu, Vol 48, Iss 10, Pp 979-982 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	cervical cancer gene therapy radiation therapy chemical treatment rhad-p53 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cervical cancer gene therapy radiation therapy chemical treatment rhad-p53 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 DONG Yaqin XU Xingyu CHEN Bo YANG Lin Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer
description	Objective To analyze the short- and long-term effect of chemoradiotherapy combined with rhAd-p53 on locally advanced cervical cancer (LACC). Methods A total of 51 patients with stage ⅡA-ⅣA LACC were divided into experimental group (chemoradiotherapy+rhAd-p53 gene therapy, RCT-p53) and control group (chemoradiotherapy, RCT). Short-term effect, long-term effect and early side-effect were evaluated. Results ORR of RCT-p53 group and RCT group were 91.7% and 62.9%, respectively (P=0.037); CR rates were 66.7% and 40.7%, respectively. There was no significant difference of early side-effects between two groups, in terms of hematologic toxicity, digestive toxicity, hepatotoxicity or renal toxicity. Five-year PFS of RCT-p53 group and RCT group were 79.8% and 51.3%, respectively (P=0.028); 5-year OS were 81.6% and 60.3%, respectively (P=0.061). Conclusion rhAd-p53 treatment has better short-term effect and long-term effect than concurrent chemoradiotherapy, without increasing early side effects.
format	article
author	DONG Yaqin XU Xingyu CHEN Bo YANG Lin
author_facet	DONG Yaqin XU Xingyu CHEN Bo YANG Lin
author_sort	DONG Yaqin
title	Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer
title_short	Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer
title_full	Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer
title_fullStr	Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer
title_full_unstemmed	Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer
title_sort	efficacy of concurrent chemoradiotherapy combined with rhad-p53 on locally advanced cervical cancer
publisher	Magazine House of Cancer Research on Prevention and Treatment
publishDate	2021
url	https://doaj.org/article/1a67fba653174b679da54844332a8ff8
work_keys_str_mv	AT dongyaqin efficacyofconcurrentchemoradiotherapycombinedwithrhadp53onlocallyadvancedcervicalcancer AT xuxingyu efficacyofconcurrentchemoradiotherapycombinedwithrhadp53onlocallyadvancedcervicalcancer AT chenbo efficacyofconcurrentchemoradiotherapycombinedwithrhadp53onlocallyadvancedcervicalcancer AT yanglin efficacyofconcurrentchemoradiotherapycombinedwithrhadp53onlocallyadvancedcervicalcancer
_version_	1718444515433381888

Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer

Ejemplares similares